IBI-334
IBI-334 is a bispecific B7-H3 and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 is afucosylated to enhance its antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors[1].
Product Specifications
UNSPSC
12352203
Target
CD276/B7-H3; EGFR
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[IBI-334]
References & Citations
[1]Jian Guan, et al. Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors. Cancer Res (2024) 84 (7_Supplement) : LB056.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1212675-01 1 mg (E-Coli)
Recombinant Bradyrhizobium japonicum Nodulation protein V (nodV), partial
Sign In for Pricing
View Details MBS1212675-02 1 mg (Yeast)
Recombinant Bradyrhizobium japonicum Nodulation protein V (nodV), partial
Sign In for Pricing
View Details